Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.
Anhui Province Key Laboratory of Major Autoimmune Diseases, 81 Meishan Road, Hefei, Anhui, China.
Clin Rheumatol. 2020 Jun;39(6):1725-1736. doi: 10.1007/s10067-020-04985-w. Epub 2020 Feb 24.
Published studies have shown contradictory results in the association of serum/plasma levels of homocysteine (HCY) with systemic lupus erythematosus (SLE). This study is to systematically evaluate the association of serum/plasma HCY levels in SLE. A search was done using PubMed, Embase, Web of Science, and ScienceDirect databases up to 7 April 2019. Thirty-six articles including 2919 SLE patients and 3120 healthy controls were finally included in this meta-analysis. The HCY levels were significantly higher in SLE patients than in healthy controls (P < 0.001). The subgroup analysis revealed that Asian, African, Arab, Mixed, White and others as well as ages (< 35 and ≥ 35) had significant higher HCY levels in SLE patients than in the healthy controls. The study indicated that patients with disease activity index scores < 8 (P < 0.001) and ≥ 8 (P = 0.003) of SLE had significant higher HCY levels as compared with the healthy controls. It was also revealed that disease duration in SLE patients for < 10 and ≥ 10 years (P < 0.001) had significant higher HCY levels as compared with the healthy controls. A significant higher HCY level for body mass index (< 23 and ≥ 23) was found as well as measurement type in SLE patients than healthy controls. This meta-analysis demonstrated higher HCY levels in patients with SLE than healthy controls, suggesting a possible role of HCY in the disease.Key Points• Homocysteine (HCY) is closely related to the mechanisms of systemic lupus erythematosus (SLE).• This study reveals a significant correlation between HCY levels and the various indexes of disease activity.• This study reveals that medication may influence HCY levels in SLE.• This study also discovers that the subgroup analysis of all the factors influences the HCY levels in SLE patients.
已发表的研究在同型半胱氨酸（HCY）的血清/血浆水平与系统性红斑狼疮（SLE）之间的相关性方面得出了相互矛盾的结果。本研究旨在系统评估 SLE 患者的血清/血浆 HCY 水平的相关性。使用 PubMed、Embase、Web of Science 和 ScienceDirect 数据库进行了检索，检索时间截至 2019 年 4 月 7 日。最终纳入了 36 篇文章，包括 2919 例 SLE 患者和 3120 例健康对照者。荟萃分析显示，SLE 患者的 HCY 水平明显高于健康对照组（P<0.001）。亚组分析显示，亚洲人、非洲人、阿拉伯人、混合人群、白种人以及其他人群，以及年龄（<35 岁和≥35 岁）<35 岁和≥35 岁）的 SLE 患者的 HCY 水平均明显高于健康对照组。研究表明，SLE 患者的疾病活动指数评分<8（P<0.001）和≥8（P=0.003）的患者的 HCY 水平明显高于健康对照组。还发现 SLE 患者的疾病持续时间<10 年和≥10 年（P<0.001）的患者的 HCY 水平明显高于健康对照组。也发现 SLE 患者的体重指数（<23 和≥23）以及测量类型与健康对照组相比，HCY 水平明显更高。本荟萃分析显示，SLE 患者的 HCY 水平明显高于健康对照组，提示 HCY 可能在疾病中起作用。
关键点
• 同型半胱氨酸（HCY）与系统性红斑狼疮（SLE）的发病机制密切相关。
• 本研究揭示了 HCY 水平与疾病活动各项指标之间的显著相关性。
• 本研究表明，药物可能会影响 SLE 患者的 HCY 水平。
• 本研究还发现，所有因素的亚组分析均会影响 SLE 患者的 HCY 水平。
